# Candel Therapeutics Inc. (CADL) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $8.82, market value $675 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Candel Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 5399.2×**. Each dollar of revenue is priced at 5399.2×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 5.3×**. The shares trade at 5.3× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -8.5%** (5-yr avg -36.8%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -73.5%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 40.5%**. Return on all capital, debt included, is 40.5%: comfortably above what that capital costs.
- **Return on assets: -15.0%**. Each dollar of assets produces -15.0% of profit.

## Growth
- **EPS growth (1 yr): 58.6%**. Earnings per share rose 58.6%.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 3.5×**. It would take 3.5 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Interest coverage: -20.3×**. Operating profit covers interest only -20.3×: fragile.
- **Current ratio: 13.49** (quick 13.49). Current assets cover the next year's liabilities 13.49 times.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Candel Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (9 analysts). 9 analysts cover Candel Therapeutics Inc.; the consensus is strong_buy, with an average price target of $22.11 (+151% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 50.9%** (YTD 43.7%, 3-mo -19.4%). The shares are up 50.9% over twelve months including dividends.
- **From 52-week high: -37.0%** (102.8% above the low). Trading 37% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 36**. An RSI of 36 is neutral.
- **Beta (1 yr): 1.99** (volatility 70%). Beta of 1.99 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CADL · Page: https://foliofundamentals.com/stocks/cadl

Not investment advice.